{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:40:56Z","timestamp":1788864056968,"version":"build-2803163510"},"reference-count":34,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"36","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2021,12,20]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> The activity of androgen-deprivation therapy (ADT) in androgen receptor\u2013positive (AR+) salivary gland carcinomas (SGCs) has been established in the past few years. Second-line treatment in castration-resistant patients is still unknown. We investigated the activity of abiraterone acetate as second-line treatment in ADT-resistant, AR+ patients with SGC. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p> This was a single-institution phase II trial. A two-stage Simon's design was applied. The primary end point was confirmed objective response rate. Secondary end points were disease control rate, safety, progression-free survival, and overall survival. Patients were eligible when the following criteria were met: histologic diagnosis of AR-overexpressing SGC, measurable disease according to RECIST 1.1, clinical and\/or radiologic progression on ADT, suppressed serum testosterone, and no limits for the number of previous chemotherapy lines. All patients received abiraterone 1 g daily plus prednisone 10 mg and luteinizing hormone-releasing hormone agonist until progression or unacceptable toxicities. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> From 2015 to 2019, 24 AR+ patients with SGC (23 men; median age 65.8 years) were treated within the study. The overall response rate was 21% (5 partial responses), with a disease control rate of 62.5%. The median duration of response was 5.82 months. Median progression-free survival was 3.65 months (95% CI, 1.94 to 5.89), and median overall survival was 22.47 months (95% CI, 6.74 to not reached). Objective response to previous ADT did not correlate with the activity of abiraterone. Adverse events (AEs) were recorded in 22 cases (92%) with grade 3 AEs in six patients (25%): fatigue (two), flushing (one), supraventricular tachycardia (one), and two non\u2013drug-related AEs. No drug-related grade 4 or 5 AEs were recorded. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> Abiraterone plus luteinizing hormone-releasing hormone agonist is active and safe as a second-line option in AR-expressing, castration-resistant SGC. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.21.00468","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T20:11:25Z","timestamp":1633119085000},"page":"4061-4068","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":58,"title":["Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor\u2013Expressing Salivary Gland Cancer: A Phase II Trial"],"prefix":"10.1200","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3315-2580","authenticated-orcid":false,"given":"Laura D.","family":"Locati","sequence":"first","affiliation":[{"name":"Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1294-6859","authenticated-orcid":false,"given":"Stefano","family":"Cavalieri","sequence":"additional","affiliation":[{"name":"Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Bergamini","sequence":"additional","affiliation":[{"name":"Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0188-9759","authenticated-orcid":false,"given":"Carlo","family":"Resteghini","sequence":"additional","affiliation":[{"name":"Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3132-844X","authenticated-orcid":false,"given":"Elena","family":"Colombo","sequence":"additional","affiliation":[{"name":"Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Calareso","sequence":"additional","affiliation":[{"name":"Radiology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6208-4084","authenticated-orcid":false,"given":"Luigi","family":"Mariani","sequence":"additional","affiliation":[{"name":"Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Quattrone","sequence":"additional","affiliation":[{"name":"Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Alfieri","sequence":"additional","affiliation":[{"name":"Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0135-0224","authenticated-orcid":false,"given":"Paolo","family":"Bossi","sequence":"additional","affiliation":[{"name":"Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Platini","sequence":"additional","affiliation":[{"name":"Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda","family":"Capone","sequence":"additional","affiliation":[{"name":"Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-4118","authenticated-orcid":false,"given":"Lisa","family":"Licitra","sequence":"additional","affiliation":[{"name":"Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0637"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.22288"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9020017"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9030021"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-019-0142-6"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19812"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2019.08.009"},{"key":"b8","volume-title":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in oncology\u2014Head and neck cancers. Version 1.2021"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00449"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23940"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx771"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1002\/hed.25035"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2016.12.016"},{"key":"b14","volume-title":"Androgen Deprivation Therapy in Advanced Salivary Gland Cancer"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.28410"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0040"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000112"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.027"},{"key":"b20","volume-title":"WHO Classification of Head and Neck Tumours","author":"El-Naggar AK","year":"2017","edition":"4"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01037-5"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702900"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00799"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903307"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.6020"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32795"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2018.09.009"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00545"},{"key":"b32","volume":"37","author":"Li BT","year":"2019","journal-title":"J Clin Oncol"},{"key":"b33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14607-2"},{"key":"b34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00573"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.21.00468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T10:54:45Z","timestamp":1653821685000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.21.00468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":34,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2021,12,20]]}},"alternative-id":["10.1200\/JCO.21.00468"],"URL":"https:\/\/doi.org\/10.1200\/jco.21.00468","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]},"assertion":[{"value":"2021-02-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}